A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects

NCT00859807 Phase 4 COMPLETED

The purpose of this study is to determine bioequivalence of amodiaquine suspension ( Pfizer) and the WHO approved reference product Flavoquine® tablet ( Sanofi Aventis).

Details

Lead sponsor	Pfizer
Phase	Phase 4
Status	COMPLETED
Enrolment	38
Start date	2009-05
Completion	2009-06

Conditions

• Falciparum Malaria

Interventions

• Flavoquine®, Camoquin® Suspension
• Flavoquine®, Camoquin® Suspension

Primary outcomes

• Cmax, AUCtlast and AUCinf for amodiaquine. — end of study

Countries

India